Contributions
Abstract: EP1595
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Peginterferon beta-1a and glatiramer acetate (GA) are both approved first-line therapies for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). These therapies have been studied in different clinical studies, and head-to-head efficacy comparisons are lacking. Propensity score matching (PSM) is a statistical method that allows the assessment of differences in treatment effects by modelling the relationship between confounders and treatment assignments (eg, in different clinical trials), such as ADVANCE and CONFIRM.
Objectives: Compare subcutaneous (SC) peginterferon beta-1a 125 mcg every 2 weeks vs SC GA 20 mg/mL once-daily on clinical efficacy endpoints at 2 years in patients from ADVANCE and CONFIRM using PSM.
Methods: PSM (1:1) based on key baseline characteristics (age, baseline expanded disability status score [EDSS], years from onset of symptoms, number of relapses in prior year, and gender) was performed on 512 ADVANCE peginterferon beta-1a patients and 350 CONFIRM GA patients. Outcomes included annualised relapse rate (ARR), which was assessed using negative binomial regression, and 12-week and 24-week confirmed disability worsening (CDW), which were evaluated using the Kaplan-Meier method and Cox proportional hazards modeling.
Results: After matching, 336 each of peginterferon beta-1a and GA patients were included. At 2 years, patients treated with peginterferon beta-1a had a significantly lower ARR (0.204 vs 0.282; rate ratio 0.724; P=0.0453), a significantly lower probability of 12-week CDW (10.0% vs 14.6%; hazard ratio (HR) 0.625; P=0.0476), and a numerically lower probability of 24-week CDW (7.7% vs 10.6%; HR 0.684; P=0.171) compared with patients treated with GA.
Conclusions: In this PSM analysis using data from two recent phase 3 trials, peginterferon beta-1a every 2 weeks showed significantly better clinical outcomes in terms of relapses and 12 week disability worsening compared to GA once-daily in patients with RRMS over 2 years.
Disclosure: Supported by Biogen.
TS: Received research support from Biogen and Novartis, and received honoraria for participation in scientific advisory boards and speaking for Acorda Therapeutics, Biogen, Genzyme, Novartis and Teva Neurosciences.
OM, CCV, AH, MLN: employees of and may hold stock and/or stock options in Biogen.
Abstract: EP1595
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: Peginterferon beta-1a and glatiramer acetate (GA) are both approved first-line therapies for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). These therapies have been studied in different clinical studies, and head-to-head efficacy comparisons are lacking. Propensity score matching (PSM) is a statistical method that allows the assessment of differences in treatment effects by modelling the relationship between confounders and treatment assignments (eg, in different clinical trials), such as ADVANCE and CONFIRM.
Objectives: Compare subcutaneous (SC) peginterferon beta-1a 125 mcg every 2 weeks vs SC GA 20 mg/mL once-daily on clinical efficacy endpoints at 2 years in patients from ADVANCE and CONFIRM using PSM.
Methods: PSM (1:1) based on key baseline characteristics (age, baseline expanded disability status score [EDSS], years from onset of symptoms, number of relapses in prior year, and gender) was performed on 512 ADVANCE peginterferon beta-1a patients and 350 CONFIRM GA patients. Outcomes included annualised relapse rate (ARR), which was assessed using negative binomial regression, and 12-week and 24-week confirmed disability worsening (CDW), which were evaluated using the Kaplan-Meier method and Cox proportional hazards modeling.
Results: After matching, 336 each of peginterferon beta-1a and GA patients were included. At 2 years, patients treated with peginterferon beta-1a had a significantly lower ARR (0.204 vs 0.282; rate ratio 0.724; P=0.0453), a significantly lower probability of 12-week CDW (10.0% vs 14.6%; hazard ratio (HR) 0.625; P=0.0476), and a numerically lower probability of 24-week CDW (7.7% vs 10.6%; HR 0.684; P=0.171) compared with patients treated with GA.
Conclusions: In this PSM analysis using data from two recent phase 3 trials, peginterferon beta-1a every 2 weeks showed significantly better clinical outcomes in terms of relapses and 12 week disability worsening compared to GA once-daily in patients with RRMS over 2 years.
Disclosure: Supported by Biogen.
TS: Received research support from Biogen and Novartis, and received honoraria for participation in scientific advisory boards and speaking for Acorda Therapeutics, Biogen, Genzyme, Novartis and Teva Neurosciences.
OM, CCV, AH, MLN: employees of and may hold stock and/or stock options in Biogen.